Skip to main content

Table 3 Subgroup analysis and meta-regression of the association between CD9 expression and disease-free survival in cancer patients

From: Increased CD9 expression predicts favorable prognosis in human cancers: a systematic review and meta-analysis

Subgroup

Number of studies

Number of patients

Pooled HR (95% CI)

p value

Heterogeneity

Meta-regression

I2 (%)

p value

p value

Cancer type

      

0.240

 Breast cancer

4

1714

0.73 (0.23–2.27)

0.583

91.1

 < 0.001

 

 Digestive system cancer

2

450

0.51 (0.25–1.03)

0.059

44.2

0.181

 

 Head and neck cancer

2

187

0.37 (0.15–0.92)

0.033

54.8

0.137

 

 Leukemia/lymphoma

2

188

0.39 (0.25–0.61)

 < 0.001

0.0

0.921

 

 Others

1

320

0.28 (0.11–0.71)

0.007

 

CD9 detection method

      

0.792

 Flow cytometry

1

112

0.41 (0.17–0.95)

0.039

 

 IHC

9

2638

0.52 (0.30–0.90)

0.020

84.8

 < 0.001

 

 RT-PCR

1

109

0.30 (0.14–0.63)

0.002

 

Publication year

      

0.033

 After 2005

5

1954

0.81 (0.41–1.62)

0.552

85.2

 < 0.001

 

 Before 2005

6

905

0.33 (0.24–0.46)

 < 0.001

0.0

0.456

 

 Race

      

0.354

 Asian

7

2240

0.58 (0.30–1.12)

0.102

87.4

 < 0.001

 

 Caucasian

4

619

0.40 (0.27–0.59)

 < 0.001

0.0

0.402

 

Sample size

      

0.896

 Fewer than 140

5

444

0.46 (0.23–0.92)

0.028

69.5

0.011

 

 More than 140

6

2415

0.49 (0.26–0.94)

0.032

86.0

 < 0.001

 
  1. CI, confidence interval; HR, hazard ratio; IHC, immunohistochemistry; RT-PCR, reverse transcription-polymerase chain reaction